Nallicheri Armaan, Mahoney Katherine M, Gutow Hanna A, Bellini Natalie, Isaacs Diana
Close Concerns, San Francisco, CA, USA.
R&B Medical Group, Williamsville, NY, USA.
touchREV Endocrinol. 2022 Jun;18(1):27-34. doi: 10.17925/EE.2022.18.1.27. Epub 2022 May 20.
Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care.
自动胰岛素输送（AID）系统在1型糖尿病（T1DM）的管理中发挥着重要作用。这些系统包括三个组成部分：连续血糖监测仪（CGM）、胰岛素泵以及一种根据CGM传感器的血糖读数来调整泵的算法。它们并非完全自动化，仍然需要用户针对食物注射大剂量胰岛素。一些AID系统具有自动校正大剂量胰岛素功能，而其他一些系统仅具有自动基础胰岛素或背景胰岛素调整功能。随着CGM变得更加精确且技术不断发展，AID系统已显示出改善的血糖结果。在随机对照试验和真实世界研究中对AID系统的临床评估表明了它们在帮助血糖管理方面的效用。在本综述中，我们比较了美国市场上可买到的AID系统并总结文献，特别关注T1DM患者的血糖达标时间。该综述还讨论了即将出现的新型AID系统，并探讨了个性化护理的相关考量因素。
